Oncolytics says pelareorep shows durable survival benefit in anal cancer
ONCY•Oncolytics Biotech said pelareorep showed durable survival data in anal cancer and described it as a potential backbone immunotherapy across HPV-driven cancers.
1. Survival data
Oncolytics Biotech reported strong durability and survival data for pelareorep in anal cancer, describing the therapy as a potential backbone immunotherapy across HPV-driven cancers.
